At least one of three PIK3CA missense mutation spots was detected in 10 (41.7%) of 24 tumor DNA samples, 7 (30.4%) of 23 circulating DNA samples collected before treatment, and 12 (29.3%) of 41 DNA samples collected during follow-up after treatment. This evidence concerns the gene PIK3CA and neoplasm.